Reply of the Authors: Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial

F&S Reports 2026 Open access

Read full text
Authors: Peng‐Hui Wang, Chun‐An Chen, Mayuko Sekiya, Kiyohiko Nakai, Junnosuke Matsushima, Ayako Nishimoto-Kakiuchi
DOI: 10.1016/j.xfre.2025.12.008
Cited by: 0
References: 3

Abstract

We thank you for providing an opportunity to respond to the Letter to the Editor concerning our manuscript (1). We have carefully reviewed the comments provided by the letter authors and have addressed each topic raised in this response letter.

Fields of Study & Subjects

Endometriosis Research and Treatment Pharmacovigilance and Adverse Drug Reactions Ectopic Pregnancy Diagnosis and Management

Publication details

Journal / source
F&S Reports
Volume
7
Issue
1
Pages
95–96
Publication date
1 February 2026
Language
EN